News
September 24, 2025
Research and Development
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
Investor
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal 
September 19, 2025
Investor
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
Investor
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
September 8, 2025
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025
September 8, 2025
Investor
Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary
September 4, 2025
Investor
Notice Regarding Execution of Loan Agreement with Financial Covenants
August 19, 2025
Investor
Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants
July 16, 2025
Research and Development
Pharma Foods’ Antibody Technology Advances as Takeda Exercises Sequence Purchase Option
June 16, 2025
Investor
Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants
September 19, 2025
Investor
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
Investor
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
September 8, 2025
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025
September 8, 2025
Investor
Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary
September 4, 2025
Investor
Notice Regarding Execution of Loan Agreement with Financial Covenants
August 19, 2025
Investor
Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants
July 16, 2025
Research and Development
Pharma Foods’ Antibody Technology Advances as Takeda Exercises Sequence Purchase Option
June 16, 2025
Investor
Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants